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Comparison of clinical course and outcome of hypophosphatemia
with and without oral phosphate supplementation in the first year
after renal transplantation: a single-center retrospective study
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Abstract
Introduction: Phosphate retention is a hallmark of chronic renal failure. The hypophosphatemia
that occurs in the early post-renal transplantation period may represent the end result of the rapid
transcellular shift of phosphate between body compartments rather than phosphate depletion. The
common practice of phosphate replacement after renal transplantation should be re-evaluated.
Methods: The changes of serum phosphate over the first 12 months after renal transplantation
were analyzed retrospectively in 30 new renal transplant recipients. Group A included nine
normophosphatemic patients who did not require a phosphate supplement. Group B included 13
hypophosphatemic patients who were given a titrated dose of an oral phosphate mixture. Group C
included eight hypophosphatemic patients who were not given phosphate supplementation.
Results: There was no difference in the duration of hypophosphatemia in Groups B and C. No
complications of hypophosphatemia were found in patients in Groups B and C. A high serum
phosphate level before transplantation was the single factor associated with post-transplantation
hypophosphatemia. No predictors of serum phosphate level after renal transplantation were found.
Conclusion: Phosphate supplementation did not alter the clinical course and outcome of
hypophosphatemia after kidney transplantation.
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intake of 800 to 1200 mg, as assessed by dietitians in the
center.
STUDY PROTOCOL
All patients were followed up twice weekly for the first
4 weeks, once weekly in the second month, once
fortnightly in the third and fourth months, once per month
in the fifth and sixth months, once every 6 weeks in
seventh and eighth months, then once bimonthly in the
subsequent months after transplantation. The immuno-
suppressive therapy was adjusted in each individual
patient based on the center's protocol.
The prescription of oral phosphate mixture was started
at 10 mL thrice a day (each milliliter contained sodium
0.567 mmol and phosphate 0.315 mmol) on some of the
hypophosphatemic patients at the discretion of the
attending physicians. Once prescribed, the dose was
titrated up with the aim of correcting the hypo-
phosphatemia. There was no strict protocol for the
titration of the oral phosphate mixture. It was usually
stopped when the serum phosphate level was normalized
for more than 2 consecutive weeks.
Three groups of patients were identified in this
retrospective study. Group A included nine normo-
phosphatemic patients who did not require an oral
phosphate mixture. Group B included 13 hypo-
phosphatemic patients who were given an oral phosphate
supplement at any time during the study period. Group
C included eight hypophosphatemic patients who had
no oral phosphate supplementation throughout the study
period.
Serum phosphate levels (normal range of our laboratory,
0.8-1.5 mmol/L) were measured at each clinic visit.
Additional measurements of the serum phosphate level
were performed at the discretion of the attending
physicians. The weekly mean serum phosphate level was
followed up in the first year after transplantation. The
trough phosphate level (trough-Pi) was the first
detectable lowest value of serum phosphate after
transplantation. Time to recover from trough-Pi was
defined as the time required for the serum phosphate level
to increase from trough-Pi to a normal level that persisted
for 2 weeks. The pretransplantation phosphate level was
the mean of the serum phosphate level over 3 months
before transplantation. A similar calculation was used to
determine the pretransplantation calcium and alkaline
phosphatase levels.
The pretransplantation intact parathyroid hormone (PTH)
level, measured by using an Immulite automated
immunoassay analyzer (Diagnostic Product, US) (normal
INTRODUCTION
Hypophosphatemia is an electrolyte disturbance
commonly found in the early post-transplantation period
(1-6) and it often persists for more than 1 year after renal
transplantation (7-9). The severity of hypophosphatemia
varies from patient to patient. In non-renal transplant
recipients, acute complications of severe hypo-
phosphatemia, defined as less than 0.32 mmol/L, are
often reported in patients with underlying medical
conditions such as alcoholism, hyperalimentation, and
diabetic ketoacidosis (10,11). The acute complications,
including rhabdomyolysis (10), red cell dysfunction (10),
leukocyte dysfunction (10), platelet dysfunction (10),
central nervous system dysfunction (10,12,13),
respiratory failure (12,14), cardiac dysfunction (15,16),
and hemolytic anemia (17), have not been reported in
renal transplant recipients during the early post-renal
transplantation period. However, persistent hypo-
phosphatemia has been implicated in the development
of osteomalacia in those with (7) and without a renal
transplant (18,19).
The approach of correcting the hypophosphatemia and
avoiding the acute complications and late effects of
hypophosphatemia is a common practice in many renal
transplant centers. Guidelines for treating hypo-
phosphatemia after renal transplantation are poorly
defined. In this retrospective study, the important points
in the management of hypophosphatemia after renal
transplantation are discussed.
METHODS
Thirty of the 34 patients who had undergone renal
transplantation during the period from January 1999 to
December 2000 in the Kwong Wah Hospital were
recruited into this retrospective study. Three patients
were excluded because of major illness occurring in the
first year after transplantation (one had gram-negative
septicemia, one had tuberculosis infection of the graft
ureter, and one had repeated intestinal obstruction). The
fourth patient was excluded because a total para-
thyroidectomy was performed before transplantation.
At the time of renal transplantation, the patients had been
on dialysis for a mean period of 20 ± 5 months (range,
0-120 months). Maintenance immunosuppression
therapy consisted of azathioprine or mycophenolate
mefetil, prednisolone, and cyclosprin. When the patients
returned to our center from the transplantation centers
in Mainland China, the first available serum phosphate
level was obtained at variable intervals (3.1 ± 0.3 weeks)
after transplantation. The serum creatinine upon
presentation to our unit was 133 ± 30 µmol/L (range,
97-198 µmol/L). The patients had had a daily phosphorus
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range, 1.1-5.7 pmol/L), was the latest measurement done
within the 12 months before transplantation. The slope
of the PTH level versus time was the rate of change of
the PTH level within the 12 months before and after renal
transplantation, using all available PTH measurements.
The outpatient records and hospital notes were reviewed
to obtain any documentation of symptoms attributable
to hypophosphatemia. These clinical data were followed
up for the first year after transplantation.
STATISTICAL ANALYSIS
The values of parameters are given as mean (± standard
error of mean) where applicable. Linear regression
analysis was used to estimate the rate of change in the
PTH level for each patient using all the available pre-
and post-transplantation PTH values. Differences among
the groups were assessed by using the non-paired Mann-
Whitney U test or the one-way analysis of variance test
where appropriate. Using the backward stepwise
selection method, linear multiple regression models were
used for multivariate analysis, with possible predicting
factors first identified by correlations using Spearman
correlation coefficient. Statistical significance was
assumed at a p value less than 0.05 (two-tailed).
RESULTS
A comparison of the demographic data of patients in
Groups A, B, and C are shown in (Table 1).
Time to first trough-Pi after transplantation
The time to the first detectable trough-Pi is shown in
Figure 1. Eighteen (60%) patients had the first detectable
trough value between the third and fourth week after
transplantation.
The profile of serum phosphate level over
the first 52 weeks after transplantation
The changes of weekly mean serum phosphate level over
the first 52 weeks after renal transplantation in 30
recipients are shown in Figure 2. The trough-Pi level
occurred at the second to fourth week after transplantation.
Nearly all patients became normophosphatemic at 6
months after renal transplantation. No patients were
hypophosphatemic at 1 year after renal transplantation.
The changes in weekly mean serum phosphate level over
the first 24 weeks after transplantation in Groups A, B,
and C were similar (Fig. 3).
Factors associated with post-
transplantation hypophosphatemia
The pretransplantation serum phosphate levels were
significantly higher in Groups B and C than in Group A
(2.31 ± 0.09 vs 1.37 ± 0.17, p<0.05). However, there
were no other biochemical parameters to distinguish
between the hypophosphatemic and normophosphatemic
patients (Table 2).
Figure 1. Distribution of first detectable trough-phosphate level (t-
trough) in 30 patients.
Figure 2. Serial serum phosphate level over the first 12 months
after renal transplantation (n = 30).*
*Serum Pi at time 0 was the mean serum phosphate concentration
measured over 3 months before transplantation. The normal range
for serum phosphate level is 0.8 to 1.5 mmol/L.
Figure 3. Change in serum phosphate levels in three groups of
patients with time after renal transplantation.*
*Serum Pi at time 0 was the mean serum phosphate concentration
measured over 3 months before transplantation. The normal range
for serum phosphate level is 0.8 to 1.5 mmol/L.
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Outcome of oral phosphate supple-
mentation in hypophosphatemic patients
There was no significant difference in the time to recover
from trough-Pi between patients in Groups B and C. The
two groups had similar rates of decrease in PTH levels
over the 12-month period. No complications of hypo-
phosphatemia were observed in any Group B or C
patients (Table 3). The patients in Group B were given
phosphate 92 ± 90 mmol during the period of hypo-
phosphatemia. There was no correlation found between
the prescribed dose of oral phosphate mixture and the
time to recover from trough-Pi, as well as the rate of
drop in PTH level.
Cross-sectional analysis of the whole
cohort of 30 patients
Using the backward stepwise selection method and with
possible predicting factors first identified by univariate
analysis, linear multiple regression revealed no
significant predictors of serum phosphate level (factors
included serum phosphate, calcium, alkaline phos-
phatase, PTH levels, the duration of dialysis before trans-
plantation, and the cumulative dose of steroid after
transplantation).
DISCUSSION
Phosphorus is mainly an intracellular anion. Most of the
intracellular phosphorus is stored in its organic form as
an intermediate substrate of protein, lipid, and
carbohydrate formation. A small proportion is present in
an inorganic form, which is important for adenosine
triphosphate resynthesis. Clinical abnormalities of hypo-
phosphatemia are related to the intracellular depletion
of adenosine triphosphate (10,20). Therefore, the
intracellular content of phosphate is much more im-
portant than the serum phosphate level in determining
the various complications of hypophosphatemia
previously reported.
In the clinical context, only the serum phosphate level,
Table 1. Comparison of the demographic data of patients in Groups A, B, and C.*
Group A (n = 9) Group B (n = 13) Group C (n = 8) p value
Sex (M/F) 3/6 8/5 7/1 NS
Age at renal transplantation, years 52 ± 11 47 ± 10 48 ± 14 NS
Duration of dialysis before renal 16 ± 10 26 ± 32 21 ± 19 NS
  transplantation, weeks
*Chi-square and one-way analysis of variance tests were used where appropriate.
Group A = normophosphatemic patients; Group B = hypophosphatemic patients given oral phosphate supplementation; Group C =
hypophosphatemic patients not given oral phosphate supplementation.
Table 2. Factors associated with the development of post-transplantation hypophosphatemia.*
Pretransplantation parameter Group A (n = 9) Groups B and C (n = 21) p value
Serum phosphate level, mmol/L 1.39 ± 0.17 2.31 ± 0.09 <0.05
Serum calcium level, mmol/L 2.26 ± 0.10 2.42 ± 0.04 NS
Serum alkaline phosphatase level, IU/L 89 ± 13 89 ± 13 NS
PTH level, pmol/L 42 ± 20 40 ± 12 NS
Duration of dialysis, weeks 16 ± 10 24 ± 6 NS
*The non-paired Mann-Whitney U test was used.
Group A = normophosphatemic patients; Group B = hypophosphatemic patients given oral phosphate supplementation; Group C =
hypophosphatemic patients not given oral phosphate supplementation; NS = the cumulative dose of steroid in both is not statistically different.
Table 3. Effect of oral phosphate supplementation on the outcome of hypophosphatemic patients*.
Pretransplantation parameter Group B (n = 13) Group C (n = 8) p value
Serum phosphate level, mmol/L 1.39 ± 0.17 2.31 ± 0.09 <0.05
Time to recover from trough-Pi, weeks 6.6 ± 1.4 5.9 ± 1.4 NS
Slope of PTH level vs time, mmol/L/week –0.42 ± 0.26 –0.42 ± 0.26 NS
Complications of hypophosphatemia – – –
*The non-paired Mann-Whitney U test was used.
Group B = hypophosphatemic patients given oral phosphate supplementation; Group C = hypophosphatemic patients not given oral phosphate
supplementation.
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rather than the intracellular content or the body store of
phosphate, is accessible. The serum phosphate level is
determined by gastrointestinal absorption, renal handling
of the phosphate, and the transcellular shift of phosphate
between body compartments (Fig. 4).
A nutritional deficiency or malabsorption of phosphorus
rarely causes hypophosphatemia. Phosphorus is present
universally in all plants and animals. Seventy percent of
the ingested phosphorus is primarily absorbed in the
jejunum and ileum in proportion to food phosphate
content (21). Active absorption of phosphorus by an Na-
dependent cotransporter has been demonstrated in rat
intestine (22).
Because glomeruli freely filter 95% of serum phosphate,
renal handling of the phosphate is of paramount
importance in altering the serum phosphate level and
regulation of the total body phosphate content. Under
normal conditions, 80% of the filtered phosphate is
reabsorbed in the convoluted and straight segments of
the proximal tubules (23). The initial step in renal
phosphate reabsorption is the movement of type II Na/
Pi cotransporters from the lumina of proximal tubules
across the microvillar brush border membranes into the
tubular cells (24). This transport is probably the rate-
determining step for phosphate reabsorption in the
proximal tubules. The activity and the number of the Na/
Pi cotransporters are modulated by numerous factors,
including dietary phosphorus content, hormones, and
metabolic factors (Table 4).
The controlling mechanism responsible for the
transcellular shift of phosphate between the extracellular
and intracellular compartments is inexplicable. But
judging from the ample intracellular content of phosphate
in bone, muscle, and cells, the shift should respond to
the metabolic needs or growth of the body at the expense
of the serum phosphate level.
The etiology for post-transplant hypophosphatemia is
multifactorial. When the allograft starts to function,
osmotic diuresis from high concentrations of urinary urea
and creatinine, a high circulating PTH level, and an
increased extracellular fluid volume from perioperative
fluid supplementation, all stimulate renal phosphate loss.
Moreover, the phosphaturic effect of steroids and
azathioprine (3) will decrease the serum phosphate level
further. However, the restoration of the normal
production of endogenous 1,25-dihydroxycalciferol (30-
32) will counteract phosphaturia by suppressing
hyperparathyroidism. The resumption of a normal to high
phosphate diet will help to replete the body store of
phosphorus. A further complication is the shift of
phosphate between different body compartments, for
example, from serum to bone, when there is involution
of the hyperparathyroidism after a successful renal
transplantation.
Consequently, a rapid change in serum phosphate,
sometimes to the degree of severe hypophosphatemia,
can occur in the early post-transplant period when the
allograft starts to function well. This does not necessarily
Figure 4. Main determinants of serum phosphate concentration.
Table 4. The influence of various factors on the action of Na/Pi cotransporters in renal proximal tubular cells.
Stimulatory (reference) Inhibitory (reference)
Phosphate-depleted diet (25,26) Phosphate-enriched diet (25,26)
Insulin (27) Parathyroid hormone (27)
Growth hormone (27) Parathyroid hormone-related protein (27)
Insuline-like growth factor I (27) Transforming growth factors α and β (27)
Calcitriol (28)* Calcitonin (27)
Thyroid hormones (28) Atrial natriuretic peptide (27)
All-trans-retinoic acid (27) Epidermal growth factor (27)
Glucocorticoid (28)
Estradiol (E2) (28)
Soluble factor from tumor-induced osteomalacia (29)
*The effects of calcitriol on Na-Pi-cotransport have been demonstrated in virtually only vitamin D-depleted cells.
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mean that the body is phosphate-deficient, because the
homeostasis of phosphate is operating together with
phosphate retention before transplantation.
In this retrospective study, the dosage of oral phosphate
supplementation was not adjusted under a strict protocol.
The hypophosphatemia lasted for more than 4 weeks in
most of the patients, either in the replaced group or the
non-replaced group. However, none of the hypo-
phosphatemic patients experienced complications of
hypophosphatemia. In the series of Higgins et al (3),
72 renal transplant recipients were free from com-
plications of hypophosphatemia even though none were
given phosphate replacement. These finding support the
notion that the renal transplant recipients are not
phosphate-depleted in the early period after renal
transplantation.
The development of post-transplant hypophosphatemia
is expected to vary widely from patient to patient as a
result of different immunosuppressive and antacid
therapies. Hampers et al (2) reported in 1969 that one-
fourth of their patients (n = 150) with good graft function
had a serum phosphate level less than 0.4 mmol/L in the
first 3 to 6 months after transplantation. At that time, the
renal transplant recipients were taking steroids,
azathioprine, and aluminium hydroxide; the latter was
used as an antiulcer prophylaxis. Higgins et al (3) found
that there were two separate periods of hypo-
phosphatemia over the 12 months after transplantation
in the 72 recipients with good graft function (serum
creatinine 75-150 µmol/L). The first trough-Pi level
occurred in the first 10 days after transplantation whereas
the second trough level, the lowest value, occurred
between 30 to 40 days after transplantation. The variation
of the serum phosphate levels was found to be in-
dependent of serum creatinine. They suggested that the
first trough level was related to the residual effect of the
phosphate binders and the insufficient endogenous
production of 1,25-(OH)2-vitamin D. In this study, most
patients had a missing serum phosphate level in the first
2 weeks after renal transplantation. The presence of two
separate trough values would not be demonstrable.
Findings in this study of a trough-Pi level at the third or
fourth week after transplantation echoes those of Higgins
et al (3). Hypophosphatemia did not persist after weeks
20 and 24 after transplantation in the study of Higgins et
al and in this study, respectively.
Factors associated with a low serum phosphate level in
the post-transplantation period have not been studied
previously. Pretransplantation hyperparathyroidism is
believed to be the most important determining factor of
post-transplant hypophosphatemia. This theoretic
association could not be demonstrated in this
retrospective study. The small sample size and the
possibility of a type I statistical error are probable
explanations. A pretransplantation intact PTH level could
not be obtained at or near the time of transplantation
when the patient only presented to us a few weeks after
the operation. Therefore, the pretransplant PTH in this
study might not reflect the true severity of hyper-
parathyroidism at the time of transplantation. However,
we have demonstrated that hyperphosphatemia before
renal transplantation is associated with post-transplant
hypophosphatemia. This finding is consistent with the
hypothesis that hyperparathyroidism is related
to the development of post-transplantation hypo-
phosphatemia.
The benefits and drawbacks of treating hypo-
phosphatemia in the early post-transplant period have
attracted much interest. Ambuhl et al (5) studied the
outcome of hypophosphatemic renal transplant recipients
with and without an oral phosphate supplement at 1
month after transplantation prospectively. All patients
had optimal graft function. Phosphate supplementation
provided an early increase in serum phosphate within 2
weeks of supplementation. However, regardless of the
supplementation, the serum phosphate concentration
increased to normal within 12 weeks (ie, at 4 months
after renal transplantation). The serum calcium and PTH
levels were unaltered during the study period. Therefore,
oral phosphate supplementation given in the early post-
transplantation period provided a faster correction of
hypophosphatemia than in spontaneous recovery.
However, there has been no report of adverse sequel
when the hypophosphatemia was left untreated. In this
retrospective study, the duration of hypophosphatemia
was unaltered by oral phosphate supplementation and
there were no complications of hypophosphatemia found
in the untreated group of patients. These results echo the
findings of Ambuhl et al (5). An early increase in serum
phosphate may not be needed if there is no detriment to
leaving it untreated in the early post-transplant period.
A drawback to oral phosphate supplementation was
observed when it was given to hypophosphatemic renal
transplant recipients at more than 6 months after
transplantation. Caravaca et al (6) confirmed that there
was a significant increase in serum phosphate level when
a daily oral phosphate supplement of 1.5 g was given for
15 days in hypophosphatemic renal transplant recipients
who had creatinine clearance greater than 46 min/min/
1.73 m2. However, the resultant metabolic disturbances
included a significant decrease in 1,25-(OH)2-vitamin
D and serum calcium levels but a significant increase in
serum PTH concentration. Therefore, the injudicious use
49
MW TONG, et alHong Kong J Nephrol 2002;4(1):43-50.
of an oral phosphate mixture, even short-term, might have
a potentially negative impact on the regression of pre-
existing hyperparathyroidism.
Suppression of the residual hyperparathyroidism using
vitamin D is another option for correcting post-transplant
hypophosphatemia. Steiner et al (4) tried daily 1,25-(OH)2
-vitamin D (range, 0.25-1 µg/d) or dihydrotachysterol
(range, 0.3-0.63 mg/d) together with calcium 1 g on 10
hypophosphatemic renal transplant recipients, with a
mean serum creatinine of 126 ± 18 µmol/L, for a mean
period of 8 weeks. There was a significant decrease in
PTH levels and the requirement for oral phosphate
supplementation, whereas the serum phosphate
concentrations increased significantly at the end of the
study. However, the risk of hypercalcemia and
hypercalciuria was 10% and 20%, respectively. Thus,
frequent monitoring of the serum calcium level is
required.
To solve the dilemma in the management of hypo-
phosphatemia after renal transplantation, a sensitive and
specific marker for detecting depletion in body phosphate
or intracellular phosphate content is needed.
CONCLUSION
Hypophosphatemia is a common finding in renal
transplant recipients. Phosphate retention before
transplantation, redistribution of phosphate from the
extracellular to intracellular compartment, and the
restoration of normal homeostasis of phosphate imply
that the body has adequate stores of phosphate in the
early post-transplant period. Hypophosphatemia in the
early post-transplant period tends to resolve spon-
taneously without complications. Oral phosphate supple-
mentation may hinder the recovery of residual hyper-
parathyroidism.
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